Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo

Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo

Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the earnings call was the biotech's pipeline and the potential for revenue in the not-too-distant future.

Metric

End of Q2 2017

Continue reading

Source: Fool.com